Transgene's intravenous IL-12-armed oncolytic virus TG-6050 cleared to enter clinic trials in France
Transgene SA has received clinical trial application (CTA) approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a phase I trial of TG-6050, a ...
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, ...
Strasbourg (France), August 27, 2024, 7:30 am CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces the ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 71, No. 10 (1974), pp. 4077-4081 (5 pages) While C-type RNA viruses are known to induce leukemias and lymphomas, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback